Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide.
1. The plasma levels and the urinary excretion of hydrochlorothiazide (HCT) have been studied after administration of single doses of 12.5 and 25 mg of the drug in solution and in combination with 100 mg of the selective beta 1-adrenoreceptor antagonist metoprolol in a rapidly dissolving tablet. 2. Metoprolol did not significantly influence the bioavailability or the time-course of HCT. 3. HCT had no significant effect on the time-course or the plasma levels of metoprolol. The average half-life, 4.4 +/- 0.9 h, is about the same as previously observed for separate doses of this drug. 4. It seems unlikely that repeated doses of the combination product studied will lead to biopharmaceutic or pharmacokinetic interactions of clinical importance.
D001682:Biological Availability; D004338:Drug Combinations; D006207:Half-Life; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000378:metabolism*; D007700:Kinetics; D008790:Metoprolol / Q000008:administration & dosage / Q000378:metabolism*; D011412:Propanolamines / Q000378:metabolism*; D013997:Time Factors
D004338:Drug Combinations; D011412:Propanolamines; D006852:Hydrochlorothiazide; D008790:Metoprolol